Loading...
Product updates, patent developments, and practical analysis. Explore the topics that matter to your work.
Subscribe via RSS
IP News
As the Chinese judiciary solidifies its role in global SEP litigation, the jurisdictional battle between ZTE and Samsung in the Chongqing Intermediate People's Court marks a critical shift. This article analyzes the strategic implications of China's growing authority in determining global FRAND licensing rates and how multinational tech companies must adapt.
IP News
With UK and Chinese courts delivering drastically different royalty determinations for Samsung and ZTE, the era of global FRAND consistency is facing its most significant challenge yet.
IP News
Moderna settles its long-standing LNP patent dispute with Arbutus and Genevant for a record-breaking $2.25 billion, setting a new benchmark for mRNA platform technology licensing.
IP News
The U.S. International Trade Commission (ITC) has officially commenced an investigation into Samsung Electronics following a complaint by Netlist, potentially threatening an import ban on key memory products including HBM and DDR5.
IP News
With an estimated $600 billion annual loss due to IP theft, the US Senate Judiciary Committee is pivoting its focus toward AI. This analysis explores the implications for global IP strategy and legal operations.
IP News
The CRISPR-Cas9 legal battle enters a critical phase as ToolGen secures key positions at the EPO, while the European Unified Patent Court (UPC) introduces the threat of multi-national injunctions.
IP News
The Federal Circuit's recent invalidation of Q Tech's patents against Walmart highlights the ongoing volatility of 35 U.S.C. § 101. We analyze why functional claims are failing and how practitioners must adapt to ensure software patent eligibility.
IP News
Moderna and Arbutus Biopharma have reached a historic $2.25 billion settlement over Lipid Nanoparticle (LNP) technology. This analysis explores the legal precedents, the valuation of platform IP, and what it means for the future of mRNA therapeutics.
IP News
As ToolGen secures key CRISPR-Cas9 RNP patents in the US and Europe, the decade-long battle over gene editing supremacy enters a high-stakes phase involving the Unified Patent Court (UPC) and billion-dollar royalties.
IP News
The landmark settlement between Moderna and Arbutus Biopharma over LNP delivery technology marks a historic turning point for the biotech industry, establishing the highest valuation yet for mRNA platform IP.
IP News
The PTAB has ruled that foreign sovereign entities do not qualify as 'persons' under the AIA, effectively barring state-owned enterprises from filing IPR petitions against US patents. This decision creates a significant procedural barrier for state-linked competitors and shifts the primary battlefield for patent invalidity to federal courts.
IP News
The entry of ToolGen into the high-stakes CRISPR patent battle against Vertex and CRISPR Therapeutics signals a new era of multi-jurisdictional litigation in gene editing.
